24+ Months: Long-Term Maintenance Decision At this point, patients and their physician make a shared decision: attempt a carefully managed tapering and transition to maintenance, or continue long-term medication for ongoing metabolic management
It's just that Australia hasn't put these drugs on the PBS here
Muscle spasms are an on-target effect of blocking this pathway, as they are also seen with the Type II receptor blocker, bimagrumab 18,21 , and were only seen in combination groups
For anyone insured: the increase does not affect you
That means: * We cant yet predict *who* will respond best * Optimal dosing for MCAS is still unknown * These medications are often used off-label for MCAS * Cost and access remain real barriers That said, the authors strongly emphasize something important: many MCAS patients responded to much lower doses than those typically prescribed for diabetes or obesity, which may improve tolerability and safety
Get the data behind Personalised Semaglutide